Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Roche, Catalent
Roche comes out against allowing takeover of drug manufacturer Catalent
The CEO of pharmaceuticals giant Roche said authorities should block the takeover of contract drug manufacturer Catalent by Novo Nordisk's controlling shareholder, as it could hit competition in the booming weight-loss drug industry.
Roche CEO says Novo's Catalent buyout 'could be a problem' for smaller drugmakers
The groups behind the letter alleged that Novo Nordisk’s plant purchases could hinder not only the Danish drugmaker’s chief commercial rival, Eli Lilly, but also companies like Viking Therapeutics, Pfizer, Roche and AstraZeneca, who are working on their own metabolic offerings.
Roche CEO says antitrust regulators should block Catalent sale to Novo Foundation
The CEO of Swiss pharmaceuticals behemoth Roche (OTCQX:RHHBY) said he believes antitrust regulators should not allow Novo Nordisk Foundation's to purchase Catalent (NYSE:CTLT). "It's not a problem for us,
Roche Beats Q3 Sales Estimates as CEO Voices Opposition to Novo Holdings’ Catalent Buyout
Jefferies analyst Peter Welford noted that Roche’s pharma group came just slightly ahead of consensus expectations, driven by strong performance of its multiple sclerosis therapy Ocrevus and eye injection Vabysmo.
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
On Wednesday, Roche Holdings AG (OTC:RHHBY) released its third-quarter sales report. Sales increased 9% year over year to 15.14 billion Swiss francs (~$17.5 billion). The company’s pharmaceuticals division reported sales of 11.
Roche CEO Urges FTC to Block Novo Nordisk's Acquisition of Catalent
Roche CEO Urges FTC to Block Novo Nordisks Acquisition of Catalent Roches CEO, Thomas Schinecker, has called on authorities to prevent Novo Nordisks controlling shareholder, Novo Holdings, from acquiring contract
Roche comes out against clearing takeover of drug manufacturer Catalent
The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by Novo Nordisk's controlling shareholder, citing harm to industry peers. "It's not a problem for us,
ENDPOINTS NEWS
1d
Allowing Novo-Catalent deal to close would be ‘wrong decision’ by antitrust authorities, Roche CEO says
Antitrust regulators shouldn't clear Novo Holdings' planned acquisition of Catalent, Roche CEO Thomas Schinecker said ...
BioPharma Dive
1d
Merck acquires cancer drug startup; Elevidys ex-US sales rise
Yale spinout Modifi agreed to sell to Merck for $30 million upfront. Elsewhere, Sangamo plotted a much faster path to market ...
devdiscourse
5h
Pharmaceutical Shifts and Health Innovations: A Global Perspective
Current health news covers Roche's opposition to Catalent's takeover, cost analysis of weight-loss drugs like Wegovy, U.S.
U.S. News & World Report
7d
Consumer Groups Ask FTC to Block Novo Holdings-Catalent Deal
Roche
plans to manage the scaling up of commercial ... According to the terms of the deal, Novo Holdings would sell three of
Catalent
's factories, where injection pens are filled in sterile ...
STAT
1d
Pharmalittle: We’re reading about Novo targeting compounded obesity drugs, an Amgen ‘at risk’ launch, and more
Novo Nordisk asked the FDA to bar compounding pharmacies from making semaglutide, arguing it is too complex for the ...
devdiscourse
6d
US Unions Urge FTC to Block Novo Holdings-Catalent Deal Amid Competition Concerns
Consumer groups and labor unions have asked the FTC to block Novo Holdings' acquisition of Catalent due to competition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback